INmune Bio and Quantum Computing Inc. to Use Quantum Optimization for Alzheimer's Drug Discovery

INmune Bio (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) will run clinical and preclinical data on XPro (XPro1595) through QCi's Dirac-3S quantum optimizer combined with AI and conventional analytics. The goal is to find other diseases sharing the same biology, identify response biomarkers and advance a Phase 2b/3 program in early Alzheimer's. It is QCi's first commercial customer in pharma/biotech.

• XPro data includes preclinical work and four clinical trials
• XPro holds FDA Fast Track designation and targets soluble TNF
• Dirac-3S is a room-temperature photonic quantum optimizer
• Results will be compared with standard statistics and machine learning